Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Gains from Investment Securities: 2022-2024

Historic Gains from Investment Securities for Orchestra BioMed Holdings (OBIO) over the last 3 years, with Dec 2024 value amounting to $1.2 million.

  • Orchestra BioMed Holdings' Gains from Investment Securities fell 60.21% to $269,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 36.79%. This contributed to the annual value of $1.2 million for FY2024, which is 308.84% up from last year.
  • As of FY2024, Orchestra BioMed Holdings' Gains from Investment Securities stood at $1.2 million, which was up 308.84% from $294,000 recorded in FY2023.
  • Over the past 5 years, Orchestra BioMed Holdings' Gains from Investment Securities peaked at $1.4 million during FY2022, and registered a low of $294,000 during FY2023.
  • For the 3-year period, Orchestra BioMed Holdings' Gains from Investment Securities averaged around $948,667, with its median value being $1.2 million (2024).
  • In the last 5 years, Orchestra BioMed Holdings' Gains from Investment Securities crashed by 78.22% in 2023 and then surged by 308.84% in 2024.
  • Yearly analysis of 3 years shows Orchestra BioMed Holdings' Gains from Investment Securities stood at $1.4 million in 2022, then plummeted by 78.22% to $294,000 in 2023, then skyrocketed by 308.84% to $1.2 million in 2024.